MEETINGS - Medical Device Validation (US) February 1999:
This article was originally published in Clinica
Medical Device Validation is the subject of a meeting to be held on February 25-26 in San Francisco, California. Issues to be addressed include how to avoid and respond to 483s; when to use process verification instead of validation; incorporating risk analysis into business decisions; and statistical considerations for high quality validation testing. Contact IBC in the US for more information. Tel: +1 508 481 6400. Fax: +1 508 481 7911.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.